Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 76% of modeled bridge. Strengths: Revenue per Bed, Bed Count. Risks: Occupancy Rate. Risk-adjusted uplift: $3.2M (vs $4.2M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $1.6M | $1.6M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $1.5M | $44K | $1.6M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $247K | $732K | $978K | $3.1M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $51K | $51K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 53.6% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $402K | $804K | $1.2M | $1.6M | $1.6M | $1.6M | $1.6M |
| Denial Rate Reduction | $0 | $398K | $796K | $1.2M | $1.6M | $1.6M | $1.6M | $1.6M |
| A/R Days Reduction | $0 | $326K | $652K | $978K | $978K | $978K | $978K | $978K |
| Clean Claim Rate | $0 | $26K | $51K | $51K | $51K | $51K | $51K | $51K |
| Cumulative | $0 | $1.2M | $2.3M | $3.4M | $4.2M | $4.2M | $4.2M | $4.2M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $4.2M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 108% / 38.7x | 113% / 43.4x | 117% / 48.1x | 119% / 50.4x | 121% / 52.7x |
| 9.0x | 103% / 34.1x | 107% / 38.2x | 112% / 42.4x | 114% / 44.5x | 116% / 46.5x |
| 10.0x | 98% / 30.4x | 103% / 34.1x | 107% / 37.8x | 109% / 39.7x | 111% / 41.5x |
| 11.0x | 94% / 27.3x | 98% / 30.7x | 103% / 34.1x | 105% / 35.8x | 106% / 37.5x |
| 12.0x | 90% / 24.8x | 95% / 27.9x | 99% / 31.0x | 101% / 32.5x | 103% / 34.1x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 77% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 1.5x, adding 6.9 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $923K | — | $923K | 1.1% |
| Year 1 | $951K | +$2.8M | $3.8M | 4.7% |
| Year 2 | $979K | +$4.2M | $5.2M | 6.5% |
| Year 3 | $1.0M | +$4.2M | $5.2M | 6.5% |
| Year 4 | $1.0M | +$4.2M | $5.3M | 6.6% |
| Year 5 | $1.1M | +$4.2M | $5.3M | 6.6% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $804K | $1.2M | $1.6M | $1.9M |
| Denial Rate Reductio | $796K | $1.2M | $1.6M | $1.9M |
| A/R Days Reduction | $489K | $734K | $978K | $1.2M |
| Clean Claim Rate | $26K | $39K | $51K | $62K |
| Total | $2.1M | $3.2M | $4.2M | $5.1M |
Peer Context — Where This Hospital Sits
Key metrics vs 17 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 1.1% | -13.7% | -1.3% | 14.4% | P56 |
| Net-to-Gross | 44.0% | 42.6% | 47.2% | 53.6% | P31 |
| Occupancy | 47.6% | 28.7% | 47.2% | 57.8% | P53 |
| Rev/Bed | $8.0M | $1.5M | $2.2M | $5.2M | P88 |
| Exp/Bed | $7.9M | $1.5M | $1.9M | $5.0M | P94 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.